Gubra AS (GUBRA) DKK1

Sell:660.00 DKKBuy:662.00 DKK12.00 DKK (1.79%)

Prices delayed by at least 15 minutes
Sell:660.00 DKK
Buy:662.00 DKK
Change:12.00 DKK (1.79%)
Prices delayed by at least 15 minutes
Sell:660.00 DKK
Buy:662.00 DKK
Change:12.00 DKK (1.79%)
Prices delayed by at least 15 minutes

Company Information

About this company

Gubra A/S is a Denmark-based biotechnology company specialized in high-end pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases. The Company’s operations are anchored around its advanced technology platforms and utilization of automation, robotization and digitalization, including machine learning (ML) and artificial intelligence (AI). The Company's business activity are divided into two segments: The CRO Segment offers specialized profitable pre-clinical contract research services at attractive margins within metabolic and fibrotic disease areas such as diabetes, obesity, chronic kidney disease; and The Discovery and Partnership Segment is based on an internal target and drug discovery engine for identification and design of peptide-based drug partnering candidates within metabolic and fibrotic diseases.

Key people

Jacob Jelsing
Chairman of the Board, Co-Founder
Henrik Blou
Chief Executive Officer
Niels Vrang
Co-Founder, Chief Scientific Officer
Kristian Borbos
Chief Financial Officer
Alexander Thomas Martensen-Larsen
Independent Deputy Chairman of the Board
Henriette Draebye Rosenquist
Independent Board Member
Arndt Justus Geo Schottelius
Independent Board Member
Click to see more

Key facts

  • EPIC
    -
  • Location
    Denmark
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    DK0062266474
  • Market cap
    DKK 10.99bn
  • Employees
    235
  • Shares in issue
    16.35m
  • Exchange
    Copenhagen Stock Exchange
  • Index
    Denmark-OMX-Copenhagen-All-Share-Index, TR Equity Denmark Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.